Oncternal Therapeutics, Inc.
已退市CIK 1260990fmd_13Z4GZ5EKGK62GJPDYRAD8AE1E制造业 · 医药制剂模板: 标准
覆盖范围: 2009年1月01日 至 2024年9月30日，共 59 个期间
| 项目 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | – | – | – | 3 | 2 | 3 | 4 | 1 | 1 |
| 营业成本 | – | – | – | – | – | – | – | – | – | – |
| 毛利润 | – | – | – | – | – | – | – | – | – | – |
| 研发费用 | 21 | 14 | 17 | 21 | 0 | 0 | 0 | 0 | 0 | 30 |
| 销售、一般及管理费用 | – | – | – | – | – | – | – | – | – | – |
| 营业费用合计 | 30 | 22 | 26 | 31 | 10 | 36 | 21 | 36 | 46 | 42 |
| 营业利润 | (30) | (22) | (26) | (31) | (8) | (33) | (18) | (31) | (45) | (42) |
| 利息费用 | – | – | – | – | 0 | – | – | – | – | – |
| 利息及投资收益 | – | – | – | – | 0 | 0 | 0 | 0 | 1 | 2 |
| 其他营业外收入（支出） | (0) | 0 | 0 | 0 | 1 | (1) | 0 | 0 | – | – |
| 税前利润 | (39) | – | – | – | – | – | – | – | – | – |
| 所得税费用 | – | – | – | – | – | – | – | 0 | 0 | 0 |
| 持续经营净利润 | (39) | – | – | – | – | – | – | – | – | – |
| 净利润 | (39) | (19) | (18) | (30) | (7) | (34) | (17) | (31) | (44) | (39) |
| 归属于普通股股东的净利润 | (39) | (22) | (18) | (30) | – | – | – | – | – | – |